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BACKGROUND: Rhabdomyosarcoma (RMS) is the commonest type of soft-tissue sarcoma in children. Patients with metastatic RMS
continue to have very poor prognosis. Recently, several works have demonstrated a connection between Notch pathway activation
and the regulation of cell motility and invasiveness. However, the molecular mechanisms of this possible relationship remain unclear.
METHODS: The Notch pathway was manipulated pharmacologically and genetically. The mRNA changes were analysed by quantitative
PCR and protein variations by western blot and immunofluorescence. Finally, the capabilities of RMS cells to adhere, heal a wound
and invade were assessed in the presence of neuronal cadherin (N-cadherin)- and a9-integrin-blocking antibodies.
RESULTS: Cells treated with g-secretase inhibitor showed lower adhesion capability and downregulation of N-cadherin and a9-integrin.
Genetic manipulation of the Notch pathway led to concomitant variations in N-cadherin and a9-integrin. Treatment with anti-N-
cadherin-blocking antibody rendered marked inhibition of cell adhesion and motility, while anti-a9-integrin-blocking antibody exerted
a remarkable effect on cell adhesion and invasiveness.
CONCLUSION: Neuronal cadherin and a9-integrin are postulated as leading actors in the association between the Notch pathway and
promotion of cell adhesion, motility and invasion, pointing to these proteins and the Notch pathway itself as interesting putative
targets for new molecular therapies against metastases in RMS.
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Rhabdomyosarcoma (RMS), a malignant tumour of early onset, is
the most common type of soft-tissue sarcoma in children.
Regarding histopathological criteria, RMS can be divided into
two main subtypes: embryonal and alveolar (eRMS and aRMS,
respectively). The majority of aRMS (80–85%) contain one of the
reciprocal chromosomal translocations: t(2;13)(q35;q14) or
t(1;13)(p36;q14). These translocations generate the novel fusion
genes PAX3-FOXO1 and PAX7-FOXO1, respectively (Barr et al,
1993; Davis et al, 1994). However, no characteristic translocations
have been described in eRMS. Patients with metastatic RMS have
very poor prognosis and more intense therapies are thus indicated.
Moreover, the major cause of death in these patients is the
formation of distant metastases. The cellular components that
control mobility, invasiveness and metastasis in RMS remain
largely unknown. The molecules responsible for these processes
should be identified before the development of targeted therapies
focused on reducing metastasis in this neoplasia. Recently, we
described the role of Notch pathway activation in controlling the
migration and invasiveness processes in RMS (Roma et al, 2011).
Similarly, the role of the Notch pathway in invasion and metastasis
has also been reported in osteosarcoma (Zhang et al, 2008; Zhang
et al, 2010; Engin et al, 2009) and some adult cancers, such as
colon, prostate, cervical carcinoma and glioblastoma among others
(Zayzafoon et al, 2004; Pang et al, 2010; Chigurupati et al, 2010;
Christofori, 2011).
The acquisition of invasive properties by cancer cells during
tumour progression is closely linked to changes in the expression
of adhesion molecules that mediate the interaction of cancer cells
with their surrounding cells and extracellular matrix. During
tumour progression, malignant cells typically downregulate
proteins that mediate adhesion to basal membrane and neighbour-
ing cells and, at the same time, promote the expression of adhesion
molecules that facilitate dynamic interaction with extracellular
matrix components (Mariotti et al, 2007). A paradigmatic example
of this phenomenon is the cadherin switch, frequently observed in
the epithelial–mesenchymal transition of epithelial cancer cells
(Cavallaro et al, 2002; Hazan et al, 2004). During this transition,
E-cadherin expression is downregulated with concomitant
enhancement of neuronal cadherin (N-cadherin) expression,
which correlates with the acquisition of greater invasiveness and
metastatic potential by malignant cells.
Neuronal cadherin (N-cadherin or cadherin-2) is a member of the
classical type I cadherin family, which is critically involved in tissue
development and maintenance. Like other classical type I cadherins,
N-cadherin contains a large N-terminal extracellular domain com-
posed of five tandem-repeated domains, a transmembrane segment
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and a cytoplasmatic C-terminal domain able to interact with catenins
(Mariotti et al, 2007). Although the mechanism by which increased
N-cadherin expression promotes malignancy is not fully understood,
in a subset of primary tumour cells, it is thought to promote adhesion
of malignant cells to N-cadherin-expressing stromal or endothelial
cells, thereby facilitating invasion and migration of tumour cells to
distant sites (Sandig et al, 1997; Qi et al, 2005). Several experiments
have demonstrated that the expression of N-cadherin suffices to
promote invasion and metastasis in some cancers (Nieman et al, 1999;
Hazan et al, 2000; Li et al, 2009).
The superfamily of integrins includes several transmembrane
cell adhesion proteins that bind to extracellular matrix, cell surface
and soluble ligands. All integrins act as heterodimers composed of
a- and b- subunits. The a- and b-polypeptidic chains are distinct
with no detectable homology between them (Takada et al, 2007).
The heterodimer a9b1 has been implicated in several processes
that entail dynamic interaction between cells and extracellular
matrix, such as re-epithelialisation during cutaneous wound
healing (Singh et al, 2009), cell adhesion in medulloblastoma and
in hematopoietic progenitor cells (Fiorilli et al, 2008; Schreiber
et al, 2009) and finally, cell migration in neoplasic and non-
neoplasic cells (Gupta and Vlahakis, 2009; Oommen et al, 2011).
The main objective of this work was to demonstrate the
existence of a connection between Notch pathway activation and
the regulation of mechanisms underlying cell motility and
invasiveness in RMS. It has been previously suggested that Notch1
and Notch3 signalling may promote an upregulation of N-cadherin
expression in primary melanoma (Liu et al, 2006; Wang et al,
2007); however, the molecular mechanisms of this possible
relationship remain unclear. Moreover, as we demonstrated
recently, the Notch pathway mediates RMS cell motility and
invasiveness (Roma et al, 2011). The oncogenic potential of the
Notch pathway was first described in acute T-cell lymphoblastic
leukaemia in the late 1980s (Radtke et al, 1999). An abnormal
upregulation of the Notch pathway has also been reported in
ovarian (Park et al, 2006), breast (Glahan and Callahan, 1997) and
other cancers (Nickoloff et al, 2003). With respect to paediatric
malignancies, Notch signalling appears to contribute essentially to
osteosarcoma metastasis (Zhang et al, 2008; Zhang et al, 2010) and
proliferation (Tanaka et al, 2009); Notch signalling also promotes
medulloblastoma cancer stem cell survival (Fan et al, 2006) and
contributes to angiogenesis in neuroblastoma (Funahashi et al,
2008). The four Notch receptors are synthesised as precursor
proteins that are processed by furin-like enzymes in the trans-
Golgi compartment. This cleavage leads to the production of a
heterodimeric Notch receptor, which is further processed at the
cell surface in a ligand-dependent manner by a- and g-secretase. The
a-secretase cleavage occurs at an extracellular site and removes the
Notch ectodomain, whereas g-secretase cleavage occurs in the Notch
transmembrane domain, leading to the release of the intracellular
Notch fragment (NICD) that translocates to the nucleus where it
binds to CSL (CBF1-Su(H)-Lag1) transcription repressors, convert-
ing them into transcriptional activators. The targets of these
transcription factors in vertebrates are typified by Hes and Hey
genes (Artavanis-Tsakonas et al, 1999; Luo et al, 2005). The possible
demonstration of a connection between Notch signalling and the
expression of adhesion molecules may shed light on the unknown
molecular mechanism of the Notch-mediated invasive phenotype of
RMS cells and allow us to adopt new therapeutic approaches to the
fight against metastases in this neoplasia.
MATERIALS AND METHODS
Cell culture, transfections and drug treatments
RH30, CW9019 and HTB82 RMS cell lines were grown in MEM
medium with Earle’s Salts, supplemented with 10% FCS, 2 m
M L-glutamine, 1 mM sodium pyruvate, 1 non-essential aminoa-
cids, 100 U ml 1 penicillin and 0.1 mg ml 1 streptomycin (all
culture reagents supplied by PAA Laboratories, Haidmannweg,
Austria) and maintained at 37 1C in a 5% CO2 water-jacketed
incubator. Full-length dnMAML1, Delta and Hes1 complementary
DNAs (cDNAs) were generously provided by Dr Anna Bigas
(Institut Municipal d’Investigació Mèdica, Barcelona, Spain). The
full-length NICD cDNA was a kind gift from Dr Rosanna Paciucci
(Institut de Recerca Hospital Vall d’Hebron, Barcelona, Spain). All
cDNAs used were cloned into a pCDNA3.1 vector, except
dnMAML1 that was cloned into a pEGFP vector. All cDNA
transfections were carried out in parallel with the respective empty
vector as a control. Transient transfections were performed using
8 mg of plasmid DNA and FuGENE 6 transfection reagent
according to the manufacturer’s protocol (Roche, Basel,
Switzerland). Transfection efficiency was approximately 70% for
the three cell lines and was assessed by calculating the percentage
of GFP-positive cells referred to the total of cells. Transfected cells
were harvested between 48 and 72 h and processed for subsequent
assays. Gamma-secretase inhibitor (GSI)-XXI (Calbiochem, San
Diego, CA, USA) was diluted in DMSO and added to the culture
medium for 3 days at a final concentration of 4 nM as previously
described (Roma et al, 2011). Control plates were supplemented
with an equivalent volume of DMSO.
Complementary DNA microarrays
Microarrays were carried out using the Affymetrix microarray
platform and the Genechip Human Gene 1.0 ST Array; 100 ng of
total RNA were used per sample. Two plates of RH30 cells
previously treated with GSI were compared with their control
(DMSO). Quality of total RNA was assessed by Bioanalyzer Assay
(Agilent). Chips were processed on an Affymetrix GeneChip
Fluidics Station 450 and Scanner 3000. Results were analysed using
TMEV software (Saeed et al, 2006).
Western blotting
Cells were homogenised in lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 5 mg ml 1 aprotinin,
5 mg ml 1 leupeptin, 1% Triton X-100, 1% sodium deoxycholate
and 0.1% SDS) and incubated for 4 min at 90 1C. The total protein
content was measured using the DC assay kit (Bio-Rad Labora-
tories, Hercules, CA, USA), a 10% SDS–PAGE was performed and
the resolved proteins were in turn transferred onto PVDF
membranes (Bio-Rad Laboratories). Membranes were then incu-
bated with anti-Hes1 polyclonal antibody AB5702 (Millipore,
Billerica, MA, USA) diluted 1 : 200, anti-N-cadherin monoclonal
antibody C2542 (Sigma, St Louis, MO, USA) diluted 1 : 1000,
anti-a9-integrin monoclonal antibody clone 3E4 (Abnova, Aachen,
Germany) diluted 1 : 250 and anti-Notch1 (C-20) sc-6014 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1 : 500. An
anti-a-tubulin monoclonal antibody (Cell Signaling, Danvers, MA,
USA) diluted 1 : 2000 was used as a loading control.
Immunofluorescence
Each well was plated with 3 105 cells on 12-mm round glass
coverslips pre-coated with a 4% collagen-I solution (BD Bios-
ciences, Erembodegem, Belgium). After 24 h, cells were transfected
with the appropriate plasmids as described above. After 48 h, cells
were washed with PBS, fixed in 4% paraformaldehyde, incubated
with 50 mM NH4Cl and permeabilised with 0.1% Triton X-100.
Samples were then blocked with 5% FCS prior to incubation with
the following primary antibodies: anti-Hes1 AB5702 (Millipore)
diluted 1 : 50, anti-N-cadherin C2542 (Sigma) diluted 1 : 250 and
anti-a9-integrin clone 3E4 (Abnova) diluted 1 : 125. Cells were then
incubated with suitable secondary antibodies labelled with
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AlexaFluor-647 or AlexaFluor-488 (Molecular probes, Eugene, OR,
USA). Nuclei were stained with 5 ng ml 1 of Hoechst33342
(Sigma). Fluorescence was visualised in a FV1000 confocal
microscope (Olympus, Hamburg, Germany) and quantified with
Olympus Fluorview software. A minimum of 100 cells obtained
from random selected fields was evaluated.
Immunohistochemistry
Patient samples (n¼ 9) were obtained from the Vall d’Hebron
Hospital Pathology Department (kindly provided by Dr Nuria
Toran). Paraffin-embedded tissues were sliced, deparaffinised and
rehydrated, followed by antigen retrieval in 10 mM citrate buffer
(DAKO). Endogenous peroxidase activity was quenched using 1%
hydrogen peroxide. Samples were blocked and incubated with
antibodies against Hes1 (AB5702, Millipore), N-cadherin (C2542,
Sigma) and a9-integrin (3E4, Abnova), all diluted 1 : 200. After
incubation with peroxidase-conjugated secondary antibody and
peroxidase substrate, samples were counterstained with hematox-
ylin for 10 s, dehydrated and mounted. Labelling of each antibody
was evaluated using a semiquantitative method regarding the
percentage of positive cells (p25%, 26–50%, 51–75% and 475%
corresponding to a score of 1, 2, 3 and 4 respectively) and intensity
of the labelling (0–3). The assigned final score (1–7) corresponds
to the sum of the labelling and percentage of positive cell scores.
RNA isolation, retrotranscription and real-time PCR
RNA was isolated using the Quick-prep micro RNA isolation kit
following the manufacturer’s instructions (Qiagen, Valencia, CA,
USA). Samples of 2 mg of total RNA were reverse transcripted using
random primers (Invitrogen, Carlsbad, CA, USA). The reaction
mixture was incubated for 1 h at 37 1C with 200 U of Moloney
murine leukaemia virus reverse transcriptase (Promega, Madison,
WI, USA). A 40-cycle PCR based on the TaqMan assay (Applied
Biosystems, Foster City, CA, USA) was performed to detect
N-cadherin and a9-integrin (Hs00983056_m1 and Hs00979865_m1
TaqMan assays, respectively). The downstream Notch effector
Hes1 (assay Hs00172878_m1) was used to assess Notch activation.
The housekeeping gene TBP (assay Hs00172424_m1) was used as
internal control. Quantification of relative levels of each mRNA
analysed was performed by the method of (Livak and Schmittgen,
2001). All samples were tested in triplicate.
Fibronectin and collagen adhesion assay
A total of 3 105 GSI-pre-treated cells per well was seeded in a 24-
well plate previously coated with collagen or fibronectin. Cells were
then incubated at 37 1C for 15 min (RH30), 30 min (CW9019) or 1 h
(HTB82), respectively, fixed with 4% paraformaldehyde and
stained with 0.2% crystal violet. Cells were then lysed in 10%
acetic acid and the absorbance at 590 nm was determined as a
value proportional to the number of cells adhered to the substrate.
To establish the specificity of the assay for N-cadherin and
a9-integrin, some wells were treated with 20 mg ml 1 of either
N-cadherin- (GC-4, Sigma) or a9-integrin-blocking antibodies
(Y9A2, Chemicon International, Temecula, CA, USA). The control
wells were treated with an anti-a-tubulin monoclonal antibody
(Cell Signaling) at the same concentration, as isotypic control. All
measurements were taken in triplicate.
Transwell assay
Cells were trypsinised, seeded at 105 cells per well and incubated in
the presence or absence of 20 mg ml 1 of either N-cadherin or
a9-integrin-blocking antibodies for 30 min on ice. Following the
incubation, cells were plated in the upper chamber previously
coated with BD Matrigel (BD Biosciences) in an 8-mm pore-size
transwell (Corning). Basal medium containing 1% FBS in the
presence or absence of the aforementioned N-cadherin and
a9-integrin-blocking antibodies was added to each well and
incubated at 37 1C for 6, 12 and 48 h (for RH30, CW9019 and
HTB82 cell lines, respectively). The control wells were treated with
20mg ml 1 anti-a-tubulin monoclonal antibody (Cell Signaling).
Remaining cells were removed from the upper chamber with a
cotton swab, and cells migrated to the lower surface were stained
with 0.2% crystal violet, lysed in 10% acetic acid and the
absorbance at 590 nm was determined as a value proportional to
the number of cells on the lower surface of each membrane. All
analyses were made in triplicate.
Wound-healing assay
Cells were seeded on a 24-well plate (3 105 cells per well) and
incubated in the presence or absence of 20mg ml 1 of either
N-cadherin- or a9-integrin-blocking antibodies as described above.
The control wells were treated with 20mg ml 1 anti-a-tubulin
monoclonal antibody as isotypic control (Cell Signaling). A day later,
cell monolayers were scratched with a pipette tip and placed in
complete growth medium with or without the suitable blocking
antibody. The initial scratched areas were measured using the ImageJ
software (NIH, freely available at http://rsb.info.nih.gov/ij/) and serial
images of random selected fields were acquired until the healing of
the wounds was complete. Healing velocity was calculated as a
quotient between the scratched area and the time required for the
wound to heal. All analyses were made in triplicate.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation was performed following the
manufacturer’s (Millipore) instructions using 5 mg of polyclonal
rabbit antibodies against Hes1 AB5702 (Millipore) and Notch1
sc-6014 (Santa Cruz Biotechnology). The same amount of rabbit
immunoglobulin (IgG) was used as a control (Abcam). The
co-immunoprecipitated DNAs were used for PCR to amplify
N-cadherin and a9-integrin promoter regions. The primers used
were as follows: N-cadherin promoter (forward 50-ACCCAGAGA
TCAAGGAGCTG-30; reverse 50-CTCCACTTCCACCTCCACAT-30)
and a9-integrin promoter (forward 50-GAGCTCAAAAGTGCCCT
CTC-30; reverse 50-TGAGGGAGGAAAAAGAAGCA-30).
RESULTS
Pharmacological inhibition of Notch signalling impairs cell
adhesion in RMS cell lines
Cells treated with GSI showed a clear reduction in cell adhesiveness
detected in either collagen- or fibronectin-coated plates (Figure 1).
The effect produced by GSI-XXI on cell adhesiveness varied among
the cell lines analysed and according to the coating of the plate
surface; however, in general, treated cells showed a significant
reduction in adhesion that ranged from 20 to 50% in fibronectin-
coated plates (Figure 1A) and from 30 to 60% in collagen-coated
plates (Figure 1B). Cell viability was assessed by flow cytometry with
no substantial differences observed between GSI-treated and
untreated (DMSO) cells (Supplementary Figure S1). These observa-
tions fitted our hypothesis that Notch pathway may be able to
regulate some of the molecular processes that lead to cell adhesion
and migration. However, they did not rule out the possibility that
the effects observed may have been caused by effects of the drug on
other pathways or directly on cell adhesion molecules.
Pharmacological inhibition of Notch signalling significantly
reduces N-cadherin and a9-integrin expression
A cDNA microarray permitted preliminary identification of
adhesion proteins downregulated under GSI treatment. Neuronal
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cadherin and a9-integrin were selected for their downregulation
under GSI treatment, their significant expression (other proteins
downregulated but barely expressed in control samples were ruled
out) and their previously well-established involvement in cell
adhesion, motility and metastasis (Figure 2A). With the aim of
confirming the results obtained in the cDNA microarray, we
specifically analysed the expression of the two selected genes by
western blotting and qRT–PCR. Western blotting (Figure 2B)
revealed a reduction in both full-length N-cadherin and the CTF2
fragment levels. The CTF1 fragment was not detected in the RMS
cell lines analysed (not shown), thereby suggesting a negligible role
of this isoform in RMS. Levels of a9-integrin were also reduced in
cells treated with GSI. Levels of b1-integrin, the usual partner of
a9-integrin, showed no changes (not shown). The reduction in
Hes1, as a marker of effective Notch inhibition in treated cells, is
also shown in Figure 2B. Similarly, mRNA levels of both
N-cadherin and a9-integrin showed statistically significant reduc-
tions in the three cell lines, down to between 60 and 85% for
N-cadherin and to 20–50% for a9-integrin, compared with
untreated cells (100%). The mRNA expression of Hes1 was also
analysed as a marker of correct Notch inhibition and showed a
statistically significant reduction, as expected, in cells treated with
GSI (Figure 2C). Although pharmacological Notch inhibition was
not complete, reductions in N-cadherin and a9-integrin expres-
sions were significant, particularly for a9-integrin.
Although these results confirmed the N-cadherin and a9-
integrin reduction in cells treated with GSI, they failed to
demonstrate unequivocally that the effects observed could be
exclusively Notch-dependent.
Genetic modification of Notch pathway activation gives
rise to a parallel regulation of N-cadherin and a9-integrin
Seeking to rule out the possibility of the observed effects on cells
treated with Notch inhibitors being attributable to the involvement
of other pathways or to a direct effect of the drugs on N-cadherin
or a9-integrin – and therefore demonstrate that these effects
resulted from specific Notch activation – we genetically manipu-
lated Notch signalling activity by transfecting constructs contain-
ing the Notch ligand Delta1 (Delta) and a dominant negative form
of MAML1 (dnMAML1). Activation of the Notch pathway by























































































































Figure 1 Cell adhesion to fibronectin- or collagen-coated plates. Images showing a representative field of attached cells for each cell line in the presence
(GSI) or absence (DMSO) of g-secretase inhibitor and plots representing the quantification of cells attached to fibronectin- (A) or collagen-coated (B)
plates. All samples were evaluated in triplicate. Student’s t-test significance: *Po0.05, **Po0.005.
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increases in both protein and mRNA levels (Figures 3A and C).
Conversely, inhibition of the pathway by overexpression of the
dominant negative dnMAML1 produces a parallel reduction in
protein and mRNA levels of N-cadherin and a9-integrin
(Figures 3B and C). Western blot revealed the presence of full-
length N-cadherin (N-Cad FL) and the CTF2 fragment, whereas the
CTF1 fragment was not detected (not shown). Both forms of
N-cadherin detected (N-Cad FL and CTF2) and a9-integrin showed
induction when the Notch pathway was activated (overexpression
of Delta) and a clear reduction when repressed (overexpression of
dnMAML1) (Figures 3A and B). No changes were observed in the
amount of b1-integrin, the usual partner of a9-integrin (not
shown).
Immunofluorescence
Fluorescent immunocytochemistry against N-cadherin revealed
moderate expression of this protein in non-transfected cells
(Figures 4A and C). When cells underwent overactivation of the
Notch pathway (by Delta1 transfection), N-cadherin expression
was significantly increased in the three cell lines analysed and
conserved the localisation pattern of the endogenous protein in
each cell line. The staining was localised in cytoplasm and cell
membrane in RH30 and CW9019 cell lines, but more prominently
in the nucleus in HTB82, which suggests a major presence of the
CTF2 form in this cell line (also observed by western blot,
Figure 3).
The distribution of a9-integrin staining was general and showed
prominent nuclear and cytoplasmic staining. As in the results
found with N-cadherin transfections, RMS cells transfected with
Delta also showed a statistically significant increase in a9-integrin
staining compared with controls (Figures 4B and C).
Specific anti-N-cadherin- and anti-a9-integrin-blocking
antibodies reduce invasive properties of RMS cells
Seeking to demonstrate that the role of N-cadherin and a9-integrin
is critical for the Notch-mediated increase in RMS cell capability to
migrate and invade, we performed adhesion, wound-healing and
invasion assays in the presence or absence of specific blocking
antibodies against these two proteins. The main aim of these
experiments was to demonstrate whether inhibition of N-cadherin
and/or a9-integrin suffices to compensate for the increases in
adhesion, wound-healing and invasiveness detected in cells with
constitutive Notch activation. Cells transfected with Delta or NICD
showed an increase in their adhesion to fibronectin-coated plates,
which could be reverted using either anti-N-cadherin- or anti-a9-





































































































































































Figure 2 Pharmacological inhibition of Notch signalling significantly reduced N-cadherin and a9-integrin expression. (A) Complementary DNA (cDNA)
expression microarray showing the relative levels of a9-integrin (ITGA9), N-cadherin (N-Cad) and Hes1 expression in GSI-treated samples (GSI) compared
with the control (DMSO). (B) Panel of western blots showing the effects of GSI on full-length N-cadherin (N-Cad/FL) and CTF2 fragment, a9-integrin
(ITGA9), NICD and Hes1 levels compared with untreated samples (DMSO). Alpha-tubulin was used as a loading control. Below the western blot
composition, a plot depicting densitometric analysis of each band of the western blot. (C) Relative mRNA levels evaluated by quantitative PCR in the
presence (GSI) or absence (DMSO) of g-secretase inhibitor. Neuronal cadherin, a9-integrin and Hes1 mRNA levels were evaluated in triplicate. Student’s
t-test significance: *Po0.05, **Po0.005.
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blocking antibodies on healing velocity differed for N-cadherin
and a9-integrin. Thus, while N-cadherin-blocking antibody gave
rise to a significant reduction in healing velocity in the three cell
lines analysed, the anti-a9-integrin-blocking antibody did not
promote any significant decrease in the capability of cells to heal a
wound (Figure 5B). Finally, the effects observed with both
antibodies on cell invasiveness in a matrigel/transwell assay also
differed (Figure 5C). Interestingly, the a9-integrin-blocking anti-
body produced marked invasiveness impairment in this assay,
whereas only a very weak effect of N-cadherin-blocking antibody
on invasiveness was observed.
Correlation among Hes1, N-cadherin and a9-integrin in
RMS archival tumour samples
Patient sections were stained using antibodies against Hes1,
N-cadherin and a9-integrin with the aim of demonstrating the
correlation among these proteins observed in cultured RMS cell
lines. The intensity of labelling was evaluated using a semiquanti-
tative method as described above. The results obtained showed a
correlation between the expression of Hes1 with both N-cadherin
and a9-integrin (Figure 6). Although the number of samples was
limited (n¼ 9), the correlation between Hes1 and N-cadherin
yielded a Pearson correlation of 0.584 (Po0.1) and the correlation
for Hes1 and a9-integrin a value of 0.771 (Po0.05), thereby
suggesting a dependency of Hes1 expression on N-cadherin and
a9-integrin. This correlation among these proteins confirms, in
patients, the aforementioned findings in cultured cells and
suggests that Notch activation may also influence the expression
of these two adhesion proteins in tumours.
NICD and Hes1 bind to N-cadherin and a9-integrin
promoters
Chromatin immunoprecipitation assay revealed co-immunopreci-
pitation of both NICD and Hes1 with the N-cadherin and a9-
integrin promoter sequences. The control IgGs rendered no
amplification (Figure 7). These results pointed to a direct binding
of these Notch downstream effectors to the promoter regions of
N-cadherin and a9-integrin genes.
DISCUSSION
Rhabdomyosarcoma patients with metastatic disease continue to
have poor prognosis and the major cause of death in these patients
is the formation of distant metastases. The identification of


























































































































































































































Figure 3 Genetic modifications of the Notch pathway influenced N-cadherin and a9-integrin expression. Western blots showing the concomitant
variations of Notch pathway activation (NICD and Hes1) and N-cadherin (N-Cad/FL and CTF2) and a9-integrin (ITGA9) expression in RMS cells
transfected with Delta (A) or dnMAML1 (B). Below each western blot composition, a plot depicting densitometric analysis of each band of the western blot.
The variations associated with genetic modification of the Notch pathway (Delta and MAML1 transfections) observed in protein are also seen in the mRNAs
of N-cadherin, a9-integrin and Hes1 determined by quantitative PCR (C). All RNA measurements were taken in triplicate. Student’s t-test significance:
*Po0.05, **Po0.005.
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RMS may be useful for developing targeted therapies focused on
reducing metastasis in this neoplasia. Although the mechanism by
which increased N-cadherin expression promotes malignancy is
not fully understood, it is thought to promote adhesion of
malignant cells to N-cadherin-expressing stromal or endothelial
cells, thereby facilitating invasion and migration of tumour cells to
distant sites (Sandig et al, 1997; Qi et al, 2005). Although several
works have demonstrated that N-cadherin expression suffices to
promote metastasis in some cancers (Nieman et al, 1999; Hazan
et al, 2000; Li et al, 2009) and an aberrant N-cadherin expression
has been described in RMS (Soler et al, 1993), no previous
publications have shown the importance of N-cadherin for RMS
invasiveness. Herein, a central role of N-cadherin in RMS cell
adhesion and motility is demonstrated; furthermore, a new
mechanism of N-cadherin induction, mediated by Notch pathway
activation, is also proposed. Likewise, a9-integrin – forming a
heterodimer with b1-integrin – has previously been implicated in
processes, such as cell migration, involving dynamic interaction
among cells and their microenvironment (Gupta and Vlahakis,
2009; Oommen et al, 2011). However, its possible role in RMS
remains unknown. Therefore, this work represents the first
description of a pro-invasive role of a9-integrin in RMS.
We and others recently implicated the Notch pathway in
paediatric sarcoma motility and invasiveness (Zhang et al, 2008;
Roma et al, 2011); however, the molecular connection between the
Notch pathway and the process that leads to cell adhesion remains
largely obscure. A previous work described the requirement of
Notch activation in the epithelial-to-mesenchymal transition of
epithelial cells, which finally rendered a disassembly of E-cadherin
junctions, thereby permitting an increase in cell motility (Zavadil
et al, 2004). The results herein presented point to the existence of a
Notch-mediated mechanism able to positively modulate the
expression of adhesion proteins, such as N-cadherin and a9-
integrin, which may drive motility and invasiveness in neoplasic
cells, thereby permitting cancer progression. The three cell lines
studied belong to different RMS subtypes and are known to have
great biological differences. Two contain PAX/FOXO1 transloca-
tions and one bears no translocation. The fact that we consistently
found a relationship between Notch and N-cadherin and a9-
integrin in such different cell lines suggests that the mechanism
here described is a general mechanism in RMS – and perhaps in
other neoplasias – and not a mere characteristic of a particular
RMS subtype. Therefore, Notch-controlled changes in the levels of
proteins implicated in tumour cell spread, such as a down-
regulation of E-cadherin in epithelial tumours (Zavadil et al, 2004)
and an upregulation of N-cadherin and a9-integrin in a
mesenchymal tumour such as RMS, support the role of Notch as
an upstream key signalling pathway in the control of cancer

























































































RH30 CW9019 HTB82 RH30 CW9019 HTB82
Figure 4 N-cadherin and a9-integrin immunocytochemistry. Immunocytochemistry with anti-Hes1 and N-cadherin (N-Cad) antibodies (A) or Hes1 and
a9-integrin (ITGA9) antibodies (B) in cells transfected with Delta or control vector (CTRL). Staining was as follows: Hes1 (green), N-cadherin and
a9-integrin (red) and nuclei (blue). (C) Relative fluorescence quantification for Hes1, N-cadherin and a9-integrin. Student’s t-test significance: *Po0.05.
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dissemination. Furthermore, the promoter-binding study, herein
provided, pointed to a direct interaction of Hes1 and NICD to
N-cadherin and a9-integrin gene regulatory regions. NICD and
Hes1 are known to be proteins able to bind directly (Hes1) or
indirectly (NICD) to DNA, thereby influencing gene transcription.
The binding of NICD to the N-cadherin and a9-integrin promoter
regions strongly suggests a role in their transcriptional activation,
as NICD is an archetypal transcriptional activator. On the other
hand, Hes1 is a known transcriptional repressor; however, it may
also act as a transcriptional activator of certain genes (Yan et al,
2002). It is not clear whether Hes1 can exert a repressive or
activating role in the promoters of the two genes included in this
study. It is also conceivable that the relative amounts of both NICD
and Hes1 may cooperatively regulate – inducing or repressing,
depending on their relative proportion – the expression of the
N-cadherin and a9-integrin genes.
The use of pharmacological Notch pathway inhibitors, such as
GSIs, has been proposed as a therapeutic alternative in several
cancers, focused essentially on reducing cell proliferation. Several
GSIs have been actively studied as potential inhibitors of the
generation of the b-amyloid peptide associated with Alzheimer’s
disease (Selkoe and Kopan, 2003). More recently, some GSIs have
begun to be studied in phase I–II trials for patients with advanced
breast cancer and acute T-cell leukaemias (Deangelo et al, 2006;
Krop et al, 2006). Beyond the use of GSIs as anti-proliferation
agents, the results of our experiments point to GSIs as compounds
able to reduce the invasive features of tumour cells and, therefore,
suitable for use in the fight against metastasis.
Taken together, the results of this work reveal that the Notch
pathway has a significant role in the regulation of N-cadherin and
a9-integrin expression in RMS and, therefore, the Notch pathway
should be considered a key regulator of the mechanisms, such as
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Figure 5 Anti-N-cadherin- and anti-a9-integrin-blocking antibodies reduced invasive properties induced by Notch activation. Three RMS cell lines were
transfected with the constructions indicated below the bottom of each bar (pCDNA, Delta) in the presence (þ ) or absence ( ) of either N-cadherin-
blocking antibody (N-Cad Ab) or a9-integrin-blocking antibody (a9-ITG Ab) as indicated in the figure. (A) Adhesion assay on fibronectin-coated plates. The
percentage of cells attached was quantified per cell line and condition. (B) Wound-healing assay. All bars indicate the healing velocity of each cell line,
transfection and treatment (C) Matrigel/Transwell assay. Invasiveness is represented as a percentage of cells in the lower compartment, compared with the
control. The three assays were performed in three independent wells per cell line and condition. Student’s t-test significance: *Po0.05.
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cell motility and invasiveness, which lead to tumour progression.
Hence, Notch-inhibiting molecules can be considered as possible
therapeutic agents against metastasis. Furthermore, the impor-
tance of N-cadherin and a9-integrin as players directly involved in
cell attachment, migration and invasiveness in RMS is also
demonstrated, consequently pointing to these proteins as new
candidates for target-specific therapies focused on reducing
metastasis in this neoplasia.
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Figure 6 The expression of Hes1, N-cadherin and a9-integrin correlate in archival RMS tumour samples. (A) Representative sections of three patients
(34, 37 and 41) stained with anti-Hes1, N-Cad and a9-integrin antibodies. (B and C) Plots depicting the correlations between Hes1 and both N-cadherin
and a9-integrin semiquantitative scores. Pearson correlation value and significance are shown in the upper left corner in each plot.












Figure 7 Binding of NICD and Hes1 to N-cadherin and a9-integrin
promoters. Lysates from RH30 cells were analysed by ChIP assay using
specific antibodies against Hes1, NICD and rabbit IgG as a control.
Immunoprecipitated chromatin was amplified by PCR using N-cadherin and
a9-integrin promoter region-specific primers. IgG: negative control rabbit
IgG; Input: 5% of the sonicated cell lysate used for IP; H2O: PCR negative
control; M: 100 bp DNA ladder.
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A Masià et al
1382
















Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate
control and signal integration in development. Science 268: 225–232
Barr FG, Gallili N, Holich J, Biegel JA, Rovera G, Emanuel BS (1993)
Rearrangement of the PAX3 paired box gene in the paediatric solid
tumour alveolar rhabdomyosarcomas. Nat Genet 3: 113–117
Cavallaro U, Schaffhauser B, Christofori G (2002) Cadherins and the
tumour progression: is it all in a switch? Cancer Lett 176(2): 123–128
Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M,
Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S, Lathia JD, Rich
JN, Chan SL (2010) Receptor channel TRPC6 is a key mediator of Notch-
driven glioblastoma growth and invasiveness. Cancer Res 70(1): 418–427
Christofori G. Metastatic colon cancer cells negotiate the intravasation
notch (2011) Cancer Cell 19(1): 6–8
Davis RJ, D’Cruz CM, Lowell MA, Biegel JA, Barr FG (1994) Fusion of PAX7
to the FOXO1 by the variant t(1;13) (p36;q14) translocation in alveolar
rhabdomyosarcomas. Cancer Res 54: 2869–2872
Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I, Dallob
A, Matthews C, Stone J, Freedman SJ, Aster J (2006) A phase I clinical
trial of the Notch inhibitor MK-0752 in patients with T-cell acute
lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin
Oncol. ASCO Annual meeting Proceedings 24(18S): abstract 6585
Engin F, Bertin T, Ma O, Jiang MM, Wang L, Sutton RE, Donehower LA,
Lee B (2009) Notch signaling contributes to the pathogenesis of human
osteosarcomas. Hum Mol Genet 18(8): 1464–1470
Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG (2006)
Notch pathway inhibition depletes stem-like cells and blocks engraft-
ment in embryonal brain tumors. Cancer Res 66: 7445–7452
Fiorilli P, Partridge D, Staniszewska I, Wang JY, Grabacka M, So K,
Marcinkiewicz C, Reiss K, Khalili K, Croul SE (2008) Integrins mediate
adhesion of medulloblastoma cells to tenascin and activate pathways
associated with survival and proliferation. Lab Invest 88(11): 1143–1156
Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M,
Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X,
Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J (2008) A Notch1
ectodomain construct inhibits endothelial notch signaling, tumor
growth, and angiogenesis. Cancer Res 68: 4727–4735
Glahan D, Callahan R (1997) The mouse mammary tumor associated gene
INT3 is a unique member of the NOTCH gene family (NOTCH4).
Oncogene 14: 1883–1890
Gupta SK, Vlahakis NE (2009) Integrin alpha9beta1 mediates enhanced cell
migration through nitric oxide synthase activity regulated by Src tyrosine
kinase. J Cell Sci 122(12): 2043–2054
Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous
expression of N-Cadherin in breast cancer cells induces cell migration,
invasion, and metastasis. J Cell Biol 148(4): 779–790
Hazan RB, Qiao R, Keren R, Badano I, Suyama K (2004) Cadherin switch in
tumor progression. Ann N Y Acad Sci 1014: 155–163
Krop IE, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer
E, Freedman SJ, Lorusso P (2006) Phase I pharmacokinetic (PK), and
pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752
in patients (pts) with advanced breast cancer (BC) and other solid
tumors. J Clin Oncol. ASCO Annual meeting Proceedings 24(18S):
abstract 10574
Li K, He W, Lin N, Wang X, Fan QX (2009) N-Cadherin knock-down
decreases invasiveness of esophageal squamous cell carcinoma in vitro.
World J Gastroenterol 15(6): 697–704
Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X,
Herlyn M (2006) Notch1 signaling promotes primary melanoma
progression by activating mitogen-activated protein kinase/phosphati-
dylinositol 3-kinase-Akt pathways and up-regulating N-cadherin
expression. Cancer Res 66(8): 4182–4190
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data
using real-time quantitative PCR and the 2-DDCT method. Methods
25(4): 402–408
Luo D, Renault VM, Rando TA (2005) The regulation of notch signaling in
muscle stem cell activation and postnatal myogenesis. Semin Cell Dev
Biol 16: 612–622
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